FCE
NBIX icon

Fiera Capital (Europe)’s Neurocrine Biosciences NBIX Stock Holding History

Fiera Capital (Europe)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$242K Hold
5,584
– – 0.11% 32
2016
Q4 		$215K Hold
5,584
– – 0.12% 33
2016
Q3 		$282K Buy
+5,584
New +$278K 0.17% 28

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fiera Capital (Europe)'s NBIX Position: Q1 2017 in Review

Fiera Capital (Europe) held its Neurocrine Biosciences (NBIX) position steady in Q1 2017 at 5,584 shares worth $242K. The position accounts for 0.11% of the portfolio, ranked #32.

Fiera Capital (Europe) first reported a position in NBIX in Q3 2016 and has held it in 3 quarters since. The position peaked at $282K in Q3 2016. 218 funds tracked by Wall St. Rank hold NBIX as of Q1 2017.

  • Fiera Capital (Europe) held 5,584 shares of Neurocrine Biosciences worth $242K as of Q1 2017.
  • Fiera Capital (Europe) left its Neurocrine Biosciences share count unchanged in Q1 2017.
  • Neurocrine Biosciences made up 0.11% of Fiera Capital (Europe)'s portfolio in Q1 2017, its #32 holding.
  • Fiera Capital (Europe) first reported a position in Neurocrine Biosciences in Q3 2016 and has held it in 3 quarters since.
  • Fiera Capital (Europe)'s Neurocrine Biosciences position peaked at $282K in Q3 2016.
  • 218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2017.

Based on Fiera Capital (Europe)'s 13F filing for Q1 2017, filed 15 May 2017.